Tags

Type your tag names separated by a space and hit enter

Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation.
J Rheumatol. 1999 Mar; 26(3):588-90.JR

Abstract

OBJECTIVE

Antiphospholipid antibodies (aPL) are thrombophilic risk markers in patients with systemic lupus erythematosus (SLE) or primary antiphospholipid syndrome (APS). The risk factors for recurrent venous or arterial thrombosis and indications for longterm anticoagulation therapy are debated. We hypothesized that carrying a second thrombophilic defect, factor V Leiden mutation, would increase the risk for thrombosis in patients with aPL.

METHODS

Seventy-five patients with primary APS and 83 with SLE and aPL with or without thrombosis followed at 2 university hospitals were studied. Factor V mutation rate was analyzed in patients and in 200 healthy blood donors by polymerase chain reaction analysis.

RESULTS

The prevalence of factor V Leiden mutation in patients with SLE and aPL or primary APS was similar to controls. Patients with deep vein thrombosis or arterial thrombosis did not have a significantly increased rate of factor V mutation compared to controls or to patients with aPL without thrombosis.

CONCLUSION

Factor V Leiden mutation is not significantly associated with vein thrombosis in patients with aPL. However, due to the sample size we cannot rule out synergy between both factor V Leiden and aPL. A trend toward increased risk for thrombosis was detected in patients with the mutation and this should be analyzed in a larger study.

Authors+Show Affiliations

Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain. jlpablos@h12O.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10090167

Citation

Pablos, J L., et al. "Risk of Thrombosis in Patients With Antiphospholipid Antibodies and Factor V Leiden Mutation." The Journal of Rheumatology, vol. 26, no. 3, 1999, pp. 588-90.
Pablos JL, Caliz RA, Carreira PE, et al. Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation. J Rheumatol. 1999;26(3):588-90.
Pablos, J. L., Caliz, R. A., Carreira, P. E., Atsumi, T., Serrano, L., Amengual, O., Santiago, B., Khamashta, M. A., Hughes, G. R., & Gomez-Reino, J. J. (1999). Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation. The Journal of Rheumatology, 26(3), 588-90.
Pablos JL, et al. Risk of Thrombosis in Patients With Antiphospholipid Antibodies and Factor V Leiden Mutation. J Rheumatol. 1999;26(3):588-90. PubMed PMID: 10090167.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation. AU - Pablos,J L, AU - Caliz,R A, AU - Carreira,P E, AU - Atsumi,T, AU - Serrano,L, AU - Amengual,O, AU - Santiago,B, AU - Khamashta,M A, AU - Hughes,G R, AU - Gomez-Reino,J J, PY - 1999/3/25/pubmed PY - 1999/3/25/medline PY - 1999/3/25/entrez SP - 588 EP - 90 JF - The Journal of rheumatology JO - J Rheumatol VL - 26 IS - 3 N2 - OBJECTIVE: Antiphospholipid antibodies (aPL) are thrombophilic risk markers in patients with systemic lupus erythematosus (SLE) or primary antiphospholipid syndrome (APS). The risk factors for recurrent venous or arterial thrombosis and indications for longterm anticoagulation therapy are debated. We hypothesized that carrying a second thrombophilic defect, factor V Leiden mutation, would increase the risk for thrombosis in patients with aPL. METHODS: Seventy-five patients with primary APS and 83 with SLE and aPL with or without thrombosis followed at 2 university hospitals were studied. Factor V mutation rate was analyzed in patients and in 200 healthy blood donors by polymerase chain reaction analysis. RESULTS: The prevalence of factor V Leiden mutation in patients with SLE and aPL or primary APS was similar to controls. Patients with deep vein thrombosis or arterial thrombosis did not have a significantly increased rate of factor V mutation compared to controls or to patients with aPL without thrombosis. CONCLUSION: Factor V Leiden mutation is not significantly associated with vein thrombosis in patients with aPL. However, due to the sample size we cannot rule out synergy between both factor V Leiden and aPL. A trend toward increased risk for thrombosis was detected in patients with the mutation and this should be analyzed in a larger study. SN - 0315-162X UR - https://www.unboundmedicine.com/medline/citation/10090167/Risk_of_thrombosis_in_patients_with_antiphospholipid_antibodies_and_factor_V_Leiden_mutation_ L2 - http://www.diseaseinfosearch.org/result/7087 DB - PRIME DP - Unbound Medicine ER -